logo

For the Inventor, By the Inventor

Tel Aviv, Israel

Itzhak Bentwich

USPTO Granted Patents = 29 


 

Average Co-Inventor Count = 1.6

ph-index = 17

Forward Citations = 812(Granted Patents)


Location History:

  • Mishgav, IL (2009 - 2010)
  • D.N. Misgav, IL (2010)
  • Kfar Daniel, IL (2007 - 2012)
  • Misgav, IL (2010 - 2017)
  • Tel Aviv, IL (2012 - 2018)

Company Filing History:

goldMedal29 out of 64 
 
Rosetta Genomics Ltd.
 patents

Years Active: 2007-2018

Loading Chart...
Loading Chart...
Loading Chart...
29 patents (USPTO):Explore Patents
1. 9920379 - Nucleic acids related to MiR-29B-1-5P and uses thereof (2018-03-20),
2. 9890382 - Nucleic acid compositions related to MIR-138-1-3P and uses thereof (2018-02-13),
3. 9650680 - MicroRNAs and uses thereof (2017-05-16),
4. 9650679 - HSA-MIR-146B-5P-related nucleic acids and uses thereof (2017-05-16),
5. 9624556 - Viral and viral associated miRNAs and uses thereof (2017-04-18),
6. 9133453 - MicroRNAs and uses thereof (2015-09-15),
7. 8455633 - Viral and viral associated mirnas and uses thereof (2013-06-04),
8. 8236939 - Micrornas and uses thereof (2012-08-07),
9. 8207316 - HCMV-related nucleic acids and microRNA (2012-06-25),
10. 8163896 - Bioinformatically detectable group of novel regulatory genes and uses thereof (2012-04-23),
11. 8084598 - Bioionformality detectable group of novel regulatory oligonucleotides and uses thereof (2011-12-27),
12. 8039608 - Bioinformatically detectable group of novel regulatory genes and uses thereof (2011-10-18),
13. 7943754 - Bioinformatically detectable group of novel regulatory bacterial and bacterial associated oligonucleotides and uses thereof (2011-05-17),
14. 7906326 - Bioinformatically detectable group of novel regulatory oligonucleotides associated with alzheimer's disease and uses thereof (2011-03-15),
15. 7888497 - Bioinformatically detectable group of novel regulatory oligonucleotides and uses thereof (2011-02-15),

Title: The Innovations of Itzhak Bentwich: A Pioneer in Medical Biotechnology

Introduction: Itzhak Bentwich, a prolific inventor based in Tel Aviv, Israel, has made significant contributions to the field of medical biotechnology. With an impressive 29 patents to his name, Bentwich's work has advanced the understanding and treatment of prostate and lung cancer through innovative nucleic acid compositions.

Latest Patents: Bentwich's recent patents include groundbreaking discoveries in the realm of miRNAs and miRNA precursors, specifically focusing on polynucleotides related to MiR-29B-1-5P and MIR-138-1-3P. These patents offer valuable insights into the diagnosis, prognosis, and treatment of prostate and lung cancer, as well as methods for identifying potential modulators of these conditions.

Career Highlights: Itzhak Bentwich is affiliated with Rosetta Genomics Ltd., a renowned company in the biotechnology sector. His tenure at Rosetta Genomics has been marked by a dedication to pushing the boundaries of medical research and bringing cutting-edge technologies to the forefront of cancer treatment. Bentwich's leadership and expertise have been instrumental in shaping the company's success and reputation as a leader in innovative healthcare solutions.

Collaborations: Throughout his career, Itzhak Bentwich has collaborated with esteemed colleagues such as Amir Avniel and Yael Karov. These collaborations have been pivotal in fostering a collaborative environment where innovative ideas can flourish and transformative discoveries can be made. Bentwich's ability to work effectively within multidisciplinary teams highlights his commitment to advancing scientific knowledge and improving patient outcomes.

Conclusion: Itzhak Bentwich's pioneering work in the field of medical biotechnology underscores his status as a visionary inventor dedicated to revolutionizing cancer care. His patents and collaborations reflect a steadfast commitment to innovation and excellence, setting a high standard for the industry as a whole. As Bentwich continues to push the boundaries of scientific discovery, his contributions are sure to leave a lasting impact on the future of healthcare.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…